Matinas BioPharma Holdings (MTNB) Gains from Investment Securities (2015 - 2026)
Matinas BioPharma Holdings (MTNB) reported Gains from Investment Securities of $12449.0 for Q1 2026, up 1144.9% year-over-year from $1000.0 in Q1 2025, and up 77.84% quarter-over-quarter from $7000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Gains from Investment Securities (2015 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 12 years of Gains from Investment Securities data on file, last reported at $12449.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $12449.0, up 1144.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $12449.0 (up 211.22% YoY), and the FY2025 annual result was $457219.0, up 142.4% from the prior year.
- Gains from Investment Securities advanced to $12449.0 in Q1 2026 per MTNB's latest filing, from $7000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $46.0 million in Q2 2024 and troughed at $1000.0 in Q4 2023.
- A 5-year average of $9.7 million and a median of $110000.0 in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2026: Gains from Investment Securities sank 99.99% in 2023, then jumped 1144.9% in 2026.
- A 5-year view of Gains from Investment Securities shows it stood at $5000.0 in 2022, then slumped by 80.0% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then jumped by 600.0% to $7000.0 in 2025, then surged by 77.84% to $12449.0 in 2026.
- Business Quant data shows MTNB's Gains from Investment Securities at $12449.0 in Q1 2026, $7000.0 in Q4 2025, and $116500.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,449.00 |
| Mar 31, 2026 | 12,449.00 |
| Dec 31, 2025 | 7,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | 116,500.00 |
| Sep 30, 2025 | 116,500.00 |
| Jun 30, 2025 | 110,000.00 |
| Jun 30, 2025 | 110,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 872,063.00 |
| Sep 30, 2024 | 872,063.00 |
| Jun 30, 2024 | 46.03 Mn |
| Jun 30, 2024 | 46.03 Mn |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |